MCKESSON CORP — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
McKesson raised adjusted EPS guidance for fiscal 2027 to $45.60–$46.40 (from $44.20–$45.00), representing 17–19% growth. Q2 FY27 adjusted EPS was $11.68 (+18% YoY); revenues $111.0B (+8%). Key transactions: McKesson signed a definitive agreement to invest ~$1.4B for ~49% minority stake in Option Care Health (subject to closing conditions); completed acquisition of Precision Medicine Group; extended CVS pharmaceutical distribution partnership through June 2032.
Why this rating
Raised guidance + strong Q2 results are positive; however, $1.4B investment is ~1.5% of market cap—meaningful but not transformational. Option Care deal is still conditional; no material M&A closed.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.